This clinical trial is focused on studying the long-term safety and tolerability of a treatment called TAK-881 in individuals with Primary Immunodeficiency Diseases (PIDD). These are a group of disorders where part of the body’s immune system is missing or does not function properly, making it harder for the body to fight off infections. The treatment being tested, TAK-881, is a solution for infusion that contains two main components: human normal immunoglobulin and hyaluronidase (human recombinant). Human normal immunoglobulin is a blood-derived substance that helps boost the immune system, while hyaluronidase is an enzyme that helps the body absorb the immunoglobulin more effectively.

The purpose of this study is to evaluate how safe and tolerable TAK-881 is for people with PIDD over a long period. Participants in the study will receive the treatment through a method called subcutaneous infusion, which means the solution is slowly delivered under the skin using a small needle. The study will monitor participants for any side effects or reactions to the treatment, as well as how well the treatment helps in reducing infections and improving overall health. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their condition. The study will also gather information on how the treatment affects the participants’ quality of life, including their ability to perform daily activities and their satisfaction with the treatment. The study aims to provide valuable information on the long-term use of TAK-881 for managing Primary Immunodeficiency Diseases.